Welcome to our dedicated page for Hoth Therapeutics news (Ticker: HOTH), a resource for investors and traders seeking the latest updates and insights on Hoth Therapeutics stock.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for dermatological disorders and other significant medical needs. The company focuses on conditions such as eczema, chronic wounds, psoriasis, asthma, and acne. Utilizing their proprietary BioLexa Platform, Hoth Therapeutics aims to create two topical cream products to treat eczema and reduce post-procedure infections in aesthetic dermatology patients.
Hoth Therapeutics has established numerous license and partnership agreements with prestigious institutions including The George Washington University, The University of Maryland Baltimore, Isoprene Pharmaceuticals, Inc., North Carolina State University, Chelexa Biosciences, Inc., The University of Cincinnati, and Zyla Therapeutics, Inc. Notably, Hoth is co-developing a topical treatment with Zyla Therapeutics for cutaneous lupus erythematosus, an autoimmune disease that severely impacts patient quality of life.
The company’s research collaborations extend to various areas including HT-001, a potential treatment for cancer patients experiencing skin toxicities from Epidermal Growth Factor Receptor Inhibitors (EGFRI). Hoth has recently received FDA clearance to proceed with protocol amendments in its ongoing Phase 2a clinical trials for HT-001, aiming to optimize clinical outcomes.
Hoth Therapeutics has also made strides in Alzheimer's Disease research with its HT-ALZ project, targeting neuroinflammation and cognitive deficits by antagonizing the NK1 receptor. Pre-clinical research has shown promising results in improving cognitive functions among Alzheimer's patients.
In addition to their pipeline, Hoth's subsidiary Merveille.ai has been pivotal in advancing obesity treatment using artificial intelligence. The discovery of a promising new therapeutic candidate for obesity, leveraging large language model technologies, underscores their commitment to innovative health solutions.
Financially, Hoth Therapeutics recently engaged in an agreement to exercise warrants, raising approximately $4.2 million to support its working capital needs. Their strategic partnership with Venable, LLP further strengthens their intellectual property protection, vital for ongoing and future therapeutic developments.
Collaborations with Wise Systems International SRL and integration of the Nvidia BioNeMo AI platform are set to enhance Hoth's drug discovery capabilities, leveraging artificial intelligence for cutting-edge therapeutic advancements.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced its CEO, Robb Knie, will present at three investor conferences in September 2020. These events include the LD 500 Virtual Investor Conference on September 3 at 12:20 p.m. ET, the H.C. Wainwright & Co. 22nd Annual Global Investment Conference on September 16 at 1:30 p.m. ET, and the Sidoti & Company 2020 Fall Virtual Investor Conference on September 23 at 2:30 p.m. ET. Management will also be available for one-on-one meetings with investors during these events.
Hoth Therapeutics (NASDAQ: HOTH) updated shareholders on its COVID-19 initiatives and dermatological therapies. The company is advancing its pipeline, including the BioLexa platform for atopic dermatitis, and submitted for ethics board approval in Australia for clinical trials. Hoth licensed VNLG-152 for dermatological diseases and partnered with George Washington University to explore WEG-232 for Erlotinib side effects. Notably, Hoth is developing a breath-based COVID-19 testing device and a self-assembling vaccine platform, with preclinical testing underway.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) has submitted an ethics approval request to the Bellberry Human Research Ethics Committee in Australia for its upcoming clinical study of BioLexa, aimed at treating atopic dermatitis. The study will be a randomized, double-blind, vehicle-controlled trial assessing the safety, tolerability, pharmacokinetics, and efficacy of BioLexa in patients with mild to moderate atopic dermatitis. This marks a significant step in Hoth's clinical development program, as stated by CEO Robb Knie, highlighting the company's commitment to advancing innovative therapies.
Hoth Therapeutics, Inc. (NASDAQ:HOTH) announced its participation in LD Micro's Zooming with LD on August 11, 2020, at 8 AM PDT. CEO Robb Knie will present an overview of the company's operations and recent advancements, particularly the development of a breath-based COVID-19 mobile testing device. This virtual presentation marks an important opportunity for Hoth to showcase its innovations in biopharmaceuticals, especially in treating dermatological disorders and COVID-19 vaccine development. For access, use the password HOTHwithLD.
Hoth Therapeutics, Inc. (NASDAQ:HOTH) will present at LD Micro's Zooming with LD on August 11, 2020. CEO Robb Knie will discuss the company's recent developments, including a license for a breath-based COVID-19 testing device. The presentation is set for 8 AM PDT and will take place virtually via Zoom, accessible with the password HOTHwithLD. Hoth Therapeutics is focused on developing innovative therapies for dermatological conditions and is also advancing two COVID-19 vaccine prospects.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) has announced a licensing agreement for a medical device that enables rapid COVID-19 diagnostics via breath samples. Developed in collaboration with George Washington University, the device utilizes nanotechnology and AI to deliver immediate results, allowing public health professionals to conduct point-of-care testing efficiently. The initiative aims to create real-time data tracking for COVID-19 infections, enhancing public health responses during the pandemic. CEO Robb Knie emphasized the device's potential to mitigate COVID-19 spread significantly.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) has signed a licensing agreement with Isoprene Pharmaceuticals, Inc. to acquire rights to VNLG-152, a novel retinamide for dermatological diseases. This agreement follows an earlier Letter of Intent and enables Hoth to receive royalties from Isoprene’s usage of VNLG-152 in oncology. UMB researchers have validated RAMBAs’ effectiveness against breast and prostate cancer, showing superior effects compared to approved retinoids. Hoth aims to address dermatological disorders while mitigating adverse effects associated with traditional retinoid therapies.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced a sponsored research agreement with Virginia Commonwealth University (VCU) aimed at developing a potential treatment for COVID-19. Led by Dr. Michael Peters, the research focuses on optimizing peptide biomimetics to enhance their binding rates to the SARS-CoV-2 spike protein. The project is expected to leverage advanced computational resources to improve peptide stability and efficacy. Hoth has an exclusive license for this innovative COVID-19 therapeutic.
Hoth Therapeutics (NASDAQ: HOTH) announced an expanded research agreement with George Washington University to investigate WEG232 for treating dermatological side effects related to chemotherapy and immunotherapy. The company aims to request a Pre-IND meeting with the FDA by year-end. WEG232 has shown promise in reducing erlotinib-induced facial rash by approximately 71%. Future studies will explore optimal application timing and its effects on inflammation. CEO Robb Knie expressed optimism about advancing this much-needed therapeutic for cancer patients.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced the publication of a white paper by Scientific Advisory Board member Dr. Michael H. Peters, detailing mappings of the COVID-19 virus spike protein. The company has licensed exclusive technology from VCU for a novel peptide therapeutic aimed at preventing spike protein binding, potentially slowing COVID-19 transmission. This peptide binds with high affinity to the SARS-CoV-2 spike protein, blocking its attachment to human cells. Hoth is also advancing its pipeline focused on dermatological disorders and COVID-19 vaccine prospects.
FAQ
What is the current stock price of Hoth Therapeutics (HOTH)?
What is the market cap of Hoth Therapeutics (HOTH)?
What is Hoth Therapeutics, Inc.?
What conditions does Hoth Therapeutics focus on?
What is the BioLexa Platform?
Who are some of Hoth Therapeutics' partners?
What is HT-001?
What recent advancements have been made in Alzheimer's Disease research by Hoth Therapeutics?
How is Hoth Therapeutics advancing obesity treatment?
What financial actions has Hoth Therapeutics recently taken?
What is the significance of Hoth Therapeutics' partnership with Venable, LLP?
How is artificial intelligence being used by Hoth Therapeutics?
